COVID-19 Outcomes and Diabetes Mellitus : A Comprehensive Multicenter Prospective Cohort Study
The link between type 2 diabetes (T2D) and the severe outcomes of COVID-19 has raised concerns about the optimal management of patients with T2D. This study aimed to investigate the clinical characteristics and outcomes of T2D patients hospitalized with COVID-19 and explore the potential associations between chronic T2D treatments and adverse outcomes. This was a multicenter prospective cohort study of T2D patients hospitalized with COVID-19 in Greece during the third wave of the pandemic (February-June 2021). Among the 354 T2D patients included in this study, 63 (18.6%) died during hospitalization, and 16.4% required ICU admission. The use of DPP4 inhibitors for the chronic management of T2D was associated with an increased risk of in-hospital death (adjusted odds ratio (adj. OR) 2.639, 95% confidence interval (CI) 1.148-6.068, p = 0.022), ICU admission (adj. OR = 2.524, 95% CI: 1.217-5.232, p = 0.013), and progression to ARDS (adj. OR = 2.507, 95% CI: 1.278-4.916, p = 0.007). Furthermore, the use of DPP4 inhibitors was significantly associated with an increased risk of thromboembolic events (adjusted OR of 2.249, 95% CI: 1.073-4.713, p = 0.032) during hospitalization. These findings highlight the importance of considering the potential impact of chronic T2D treatment regiments on COVID-19 and the need for further studies to elucidate the underlying mechanisms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Microorganisms - 11(2023), 6 vom: 27. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akinosoglou, Karolina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 01.07.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/microorganisms11061416 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358762308 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358762308 | ||
| 003 | DE-627 | ||
| 005 | 20231226075428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/microorganisms11061416 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358762308 | ||
| 035 | |a (NLM)37374918 | ||
| 035 | |a (PII)1416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akinosoglou, Karolina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Outcomes and Diabetes Mellitus |b A Comprehensive Multicenter Prospective Cohort Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The link between type 2 diabetes (T2D) and the severe outcomes of COVID-19 has raised concerns about the optimal management of patients with T2D. This study aimed to investigate the clinical characteristics and outcomes of T2D patients hospitalized with COVID-19 and explore the potential associations between chronic T2D treatments and adverse outcomes. This was a multicenter prospective cohort study of T2D patients hospitalized with COVID-19 in Greece during the third wave of the pandemic (February-June 2021). Among the 354 T2D patients included in this study, 63 (18.6%) died during hospitalization, and 16.4% required ICU admission. The use of DPP4 inhibitors for the chronic management of T2D was associated with an increased risk of in-hospital death (adjusted odds ratio (adj. OR) 2.639, 95% confidence interval (CI) 1.148-6.068, p = 0.022), ICU admission (adj. OR = 2.524, 95% CI: 1.217-5.232, p = 0.013), and progression to ARDS (adj. OR = 2.507, 95% CI: 1.278-4.916, p = 0.007). Furthermore, the use of DPP4 inhibitors was significantly associated with an increased risk of thromboembolic events (adjusted OR of 2.249, 95% CI: 1.073-4.713, p = 0.032) during hospitalization. These findings highlight the importance of considering the potential impact of chronic T2D treatment regiments on COVID-19 and the need for further studies to elucidate the underlying mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a DPP4 inhibitor | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a dipeptidyl-peptidase IV inhibitors | |
| 650 | 4 | |a disease severity | |
| 650 | 4 | |a hypoglycemic agents | |
| 650 | 4 | |a in-hospital complications | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a type 2 | |
| 700 | 1 | |a Schinas, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Bletsa, Evanthia |e verfasserin |4 aut | |
| 700 | 1 | |a Bristianou, Magdaline |e verfasserin |4 aut | |
| 700 | 1 | |a Lanaras, Leonidas |e verfasserin |4 aut | |
| 700 | 1 | |a Michailides, Charalambos |e verfasserin |4 aut | |
| 700 | 1 | |a Katsikas, Theodoros |e verfasserin |4 aut | |
| 700 | 1 | |a Barkas, Fotios |e verfasserin |4 aut | |
| 700 | 1 | |a Liberopoulos, Evangelos |e verfasserin |4 aut | |
| 700 | 1 | |a Kotsis, Vasileios |e verfasserin |4 aut | |
| 700 | 1 | |a Tentolouris, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Grigoropoulou, Pinelopi |e verfasserin |4 aut | |
| 700 | 1 | |a Frangou, Archontoula |e verfasserin |4 aut | |
| 700 | 1 | |a Basoulis, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Alexiou, Zoi |e verfasserin |4 aut | |
| 700 | 1 | |a Daganou, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Bostantzoglou, Clementine |e verfasserin |4 aut | |
| 700 | 1 | |a Dimakopoulou, Vasiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Koutsoukou, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Pefanis, Angelos |e verfasserin |4 aut | |
| 700 | 1 | |a Baraboutis, Ioannis G |e verfasserin |4 aut | |
| 700 | 1 | |a Agelonidou, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Tentolouris, Nikolaos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microorganisms |d 2013 |g 11(2023), 6 vom: 27. Mai |w (DE-627)NLM247050237 |x 2076-2607 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:6 |g day:27 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/microorganisms11061416 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 6 |b 27 |c 05 | ||